Article
A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors
5 Mar 2024
Abstract excerpt
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer therapy. However, <50% of patients have an objective response, and nearly all patients develop resistance during therapy. To elucidate the underlying mechanisms, we constructed an interpretable deep learning model of the response to palbociclib, a CDK4/6i, based on a reference map of multiprotein assemblies in cancer. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
